Literature DB >> 11711215

Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons.

S Lin1, Y Zhang, R Dodel, M R Farlow, S M Paul, Y Du.   

Abstract

Minocycline, a semisynthetic second-generation tetracycline, was reported to have neuroprotective effects in models of global and focal cerebral ischemia, the R6/2 mouse model of Huntington disease, as well as glutamate-induced neurotoxicity in mixed neuronal/glial cultures. It was suggested that neuroprotective effects of minocycline resulted from inhibition of microglial/astroglial activation 'Proc. Natl. Acad. Sci. USA 95 1998 15769'. To determine whether or not minocycline is able to directly protect neurons against injury insults and to delineate its neuroprotective mechanism(s), we treated cultured rat cerebellar granule neurons (CGN) with nitric oxide (NO) in the presence or absence of minocycline. We found that minocycline protected neurons against NO-induced neuronal death in a concentration-dependent fashion. Consistent to other reports, NO was able to induce p38 MAP kinase phosphorylation at 3-6 h and such an induction could be significantly inhibited by minocycline. Furthermore, SB 203580, a p38 MAP kinase inhibitor, almost completely attenuated NO-induced neuronal death of CGN as well. These results suggest that minocycline is able to block NO-induced neurotoxicity in CGN by inhibiting NO-induced phosphorylation of p38 MAP kinase. Our finding may explain the neuroprotective mechanism of minocycline in those neurodegenerative models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711215     DOI: 10.1016/s0304-3940(01)02324-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  39 in total

1.  Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons.

Authors:  I N Singh; N El-Hage; M E Campbell; S E Lutz; P E Knapp; A Nath; K F Hauser
Journal:  Neuroscience       Date:  2005-08-19       Impact factor: 3.590

Review 2.  Mitogen-activated protein kinase p38 in HIV infection and associated brain injury.

Authors:  Kathryn E Medders; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-01       Impact factor: 4.147

3.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

4.  Minocycline increases the activity of superoxide dismutase and reduces the concentration of nitric oxide, hydrogen peroxide and mitochondrial malondialdehyde in manganese treated Drosophila melanogaster.

Authors:  Marylú Mora; Ernesto Bonilla; Shirley Medina-Leendertz; Yanauri Bravo; José Luis Arcaya
Journal:  Neurochem Res       Date:  2014-04-23       Impact factor: 3.996

5.  Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures.

Authors:  Jayne Abraham; Patrick D Fox; Carlo Condello; Alyssa Bartolini; Sookyong Koh
Journal:  Neurobiol Dis       Date:  2012-02-16       Impact factor: 5.996

Review 6.  Microglia and inflammation: conspiracy, controversy or control?

Authors:  Adelaide Fernandes; Leonor Miller-Fleming; Teresa F Pais
Journal:  Cell Mol Life Sci       Date:  2014-07-10       Impact factor: 9.261

7.  Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors.

Authors:  Marta Imbesi; Tolga Uz; Radmila Manev; Rajiv P Sharma; Hari Manev
Journal:  Neurosci Lett       Date:  2008-10-07       Impact factor: 3.046

8.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

9.  Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia.

Authors:  Mark R Hutchinson; Alexis L Northcutt; Lindsey W Chao; Jeffrey J Kearney; Yingning Zhang; Debra L Berkelhammer; Lisa C Loram; Robert R Rozeske; Sondra T Bland; Steven F Maier; Todd T Gleeson; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2008-07-31       Impact factor: 7.217

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.